|
|
|
16.12.25 - 19:36
|
Yunqi Capital Comments on Proxy Advisors′ Updated Recommendations, Urges Shareholders to Continue to Back the Company′s Standalone Trajectory (Business Wire)
|
|
|
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) regarding the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (SIX/NYSE: ALC).
The text of the letter is as follows:
December 17, 2025
Dear Fellow STAAR Shareholders:
Following our review of the updated reports of the proxy advisory services ISS and Glass Lewis, Yunqi Capital remains opposed to STAAR's proposed merger with Alcon, even at the revised offer price of $30.75.
We agree with the continued, strong recommendation of Glass Lewis against the merger, as well as with the extensive rationale for Glass Lewis's opposition set forth in its most rece...
|
|
|
16.12.25 - 15:15
|
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction (Business Wire)
|
|
|
Increased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company's amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stockholders will receive $30.75 per share in cash if the transaction with Alcon is consummated, representing a 74% premium to STAAR's 90-day Volume Weighted Average Price as of August 4, 2025 and a 66% premium to the closing price of STAAR common stock on August 4, 2025.
Independent industry analysts have stated:
“We think STAA shareholders should take this offer otherwise STAA shares are likely to meaningfully suffer ...
|
|
|
16.12.25 - 13:06
|
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon (Business Wire)
|
|
|
ISS Says It Would Not Be “Unreasonable for a Shareholder to Remain Opposed” to the Deal
Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom Recommend Shareholders Vote “AGAINST” the Proposed Transaction
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent proxy advisory firm, which reiterates that firm's significant concerns regarding the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC).
ISS stated in its latest report on the proposed sale of STAAR to Alcon:
“The initial sale process was deeply flawed, the circumstances create uncertainty about whether the go-shop could have cured concerns, and STAA has provided shareholders with no reason to rely on its efforts. … [In additio...
|
|
|
|
|
|
|
16.12.25 - 00:36
|
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger (Business Wire)
|
|
|
STAAR Urges Stockholders to Vote “FOR” Alcon Merger on the WHITE Proxy Card TODAY
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote “FOR” STAAR's amended merger agreement with Alcon (SIX/NYSE: ALC) at STAAR's Special Meeting of Stockholders on December 19, 2025 at 8:30 a.m. (Pacific Time).
STAAR issued the following statement:
The STAAR Board is committed to maximizing stockholder value and serving the best interests of all STAAR stockholders. In the ISS report issued today, ISS recommended a vote “FOR” the Alcon merger and noted that “uncertainties about valuation are n...
|
|
|
|
|
12.12.25 - 14:45
|
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon (Business Wire)
|
|
|
Contends STAAR's Process Was Ineffective in Establishing Competitive Auction and Securing Maximum Value for Shareholders
Argues Board's Procedural Credibility Is “Remarkably Threadbare”
Broadwood Continues to Urge Shareholders to Vote “AGAINST” Proposed Transaction
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) should vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).
Glass Lewis concluded in its report that “we do not believe there exists persuasive cause for investors to endorse the revised Alcon arrangement.” 1 The independent research firm went on to note that “in the absence of, among other alternatives, a full and unambiguous process reset unencumbered by ...
|
|
|
|
|
|
|
11.12.25 - 15:48
|
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process (Business Wire)
|
|
|
Activist Investors Have Twisted Facts Regarding STAAR's Engagement with a Potentially Interested Party During Go-Shop Process
The Potentially Interested Party Reached Out on Day 21 of 30-Day Go-Shop Process and Refused to Sign an NDA Even without a Standstill
Broadwood Partners and Yunqi Capital Continue to Distort the Truth for Their Own Benefit
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC).
Broadwood Partners, L.P. (“Broadwood”) falsely alleges there was a credible buyer who had a strong interest in acquiring STAAR and that STAAR management attempted to “run the clock” on a go-shop period in order to “ward off this well-established private equity firm.” That i...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.12.25 - 18:45
|
Broadwood Partners Responds to Alcon′s Increase to Proposed Acquisition Price of STAAR Surgical (Business Wire)
|
|
|
Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value
New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's Projections Have Not Changed Materially
Continues to Urge STAAR Shareholders to Vote “AGAINST” the Proposed Transaction
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC).
Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to oppose the proposed sale of the Company to Alcon and issued the following statement:
“STAAR spent months trying to convince the Company's shareholders that the Board had run a proper sale process and achieved a fair buyout price from Alcon. The Board also claimed tha...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
